Cidara Therapeutics Statistics
Total Valuation
CDTX has a market cap or net worth of $106.55 million. The enterprise value is -$16.90 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CDTX has 7.05 million shares outstanding. The number of shares has increased by 21.86% in one year.
| Current Share Class | 7.05M |
| Shares Outstanding | 7.05M |
| Shares Change (YoY) | +21.86% |
| Shares Change (QoQ) | +43.09% |
| Owned by Insiders (%) | 1.52% |
| Owned by Institutions (%) | 13.29% |
| Float | 3.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.71 |
| Forward PS | 18.01 |
| PB Ratio | 0.92 |
| P/TBV Ratio | 0.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.54 |
| Quick Ratio | 2.91 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -200.46% and return on invested capital (ROIC) is -40.88%.
| Return on Equity (ROE) | -200.46% |
| Return on Assets (ROA) | -23.89% |
| Return on Capital (ROIC) | -40.88% |
| Revenue Per Employee | $647,145 |
| Profits Per Employee | -$1.75M |
| Employee Count | 69 |
| Asset Turnover | 0.40 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CDTX has paid $435,000 in taxes.
| Income Tax | 435,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.08% in the last 52 weeks. The beta is 0.99, so CDTX's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | -3.08% |
| 50-Day Moving Average | 12.00 |
| 200-Day Moving Average | 13.00 |
| Relative Strength Index (RSI) | 71.48 |
| Average Volume (20 Days) | 24,557 |
Short Selling Information
The latest short interest is 64,578, so 0.92% of the outstanding shares have been sold short.
| Short Interest | 64,578 |
| Short Previous Month | 66,976 |
| Short % of Shares Out | 0.92% |
| Short % of Float | 1.84% |
| Short Ratio (days to cover) | 3.88 |
Income Statement
In the last 12 months, CDTX had revenue of $44.65 million and -$120.73 million in losses. Loss per share was -$23.94.
| Revenue | 44.65M |
| Gross Profit | -21.65M |
| Operating Income | -43.16M |
| Pretax Income | -36.02M |
| Net Income | -120.73M |
| EBITDA | -43.01M |
| EBIT | -43.16M |
| Loss Per Share | -$23.94 |
Full Income StatementBalance Sheet
The company has $127.39 million in cash and $3.94 million in debt, giving a net cash position of $123.44 million or $17.52 per share.
| Cash & Cash Equivalents | 127.39M |
| Total Debt | 3.94M |
| Net Cash | 123.44M |
| Net Cash Per Share | $17.52 |
| Equity (Book Value) | 115.63M |
| Book Value Per Share | 16.41 |
| Working Capital | 112.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$159.84 million and capital expenditures -$307,000, giving a free cash flow of -$160.15 million.
| Operating Cash Flow | -159.84M |
| Capital Expenditures | -307,000 |
| Free Cash Flow | -160.15M |
| FCF Per Share | -$22.73 |
Full Cash Flow StatementMargins
Gross margin is -48.49%, with operating and profit margins of -96.66% and -270.38%.
| Gross Margin | -48.49% |
| Operating Margin | -96.66% |
| Pretax Margin | -276.62% |
| Profit Margin | -270.38% |
| EBITDA Margin | -96.33% |
| EBIT Margin | -96.66% |
| FCF Margin | -40.13% |
Dividends & Yields
CDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.86% |
| Shareholder Yield | -21.86% |
| Earnings Yield | -113.32% |
| FCF Yield | -150.31% |
Analyst Forecast
The average price target for CDTX is $30.50, which is 101.72% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $30.50 |
| Price Target Difference | 101.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 10.87% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on April 24, 2024. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Apr 24, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
CDTX has an Altman Z-Score of -3.7 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.7 |
| Piotroski F-Score | 2 |